Navigation Links
Malignant stem cells may explain why some breast cancers develop and recur
Date:8/16/2011

PORTLAND, Ore. Mutations that are found in stem cells could be causing some breast cancers to develop and may be the reason the disease recurs. These abnormal cells are likely controlling cell functions in the tumor and, given they are not targeted by chemotherapy and radiation, they enable the disease to recur.

The mutations were discovered in a study conducted by scientists and physicians at the Oregon Health & Science University Knight Cancer Institute. The study, which examined breast cancer cells removed during surgery, was recently published online in the Annals of Surgical Oncology.

"By studying normal and malignant cells that were collected from breast tissues removed during surgery, we were able to look at what is occurring in the body," said SuEllen J. Pommier, Ph.D., the lead author of the study and associate research professor in the division of surgical oncology at the OHSU Knight Cancer Institute.

Working with samples taken directly from surgeries made the findings in this study possible, Pommier said, because the biology of breast stem cells could be compared with their malignant counterparts in a way that hadn't been done before. The cultured cell lines used in most studies can't provide accurate information about normal breast stem cells.

The study, which was funded primarily by the Avon Foundation for Women, may prove that some current therapies that target mutations in the tumor won't be effective in stamping out the disease for some patients. It also suggests that more research should be done in two areas:

  • Determining the role of PIK3CA/AKT1 signaling mutations, which were found in 73 percent of the tumors in this study of fresh surgical specimens an occurrence rate that is much higher than previously detected in stored samples.
  • And, exploring the importance of the loss of CD24 expression, which previously was considered a requirement for breast cancer stem cells, but may not be
    '/>"/>

Contact: Elisa Williams
willieli@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Professor discovers way to slow the growth of malignant melanoma
2. Viral life cycle of malignant catarrhal fever explained
3. Gorillas carry malignant malaria parasite, study reports
4. CSHL study shows that some malignant tumors can be shut down after all
5. Researchers find first evidence of virus in malignant prostate cells
6. Childhood eye tumor made up of hybrid cells with jumbled development
7. Stem cells central to pathogenesis of mature lymphoid tumors
8. Gladstone scientists offer new insight into the regulation of stem cells and cancer cells
9. A novel mechanism that regulates pro-inflammatory cells is identified
10. Researchers use human cells to engineer functional anal sphincters in lab
11. Researchers gain new insights into how tumor cells are fed
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Malignant stem cells may explain why some breast cancers develop and recur 
(Date:3/23/2015)... --  HOYOS Labs , a leading global authentication infrastructure ... Company will demonstrate multiple biometrics-based technologies under its identity ... on March 23 through 25, 2015, in ... IEEE Biometric Open Protocol Standard; free biometrics-based consumer app, ... system. BOPS was invented by HOYOS Labs and contributed ...
(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has ... Strategic Business Report" report to their offering. ... US$ Thousands. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... World. Annual estimates and forecasts are provided for ...
(Date:3/18/2015)... March 18, 2015 As mobile payments ... revolutionary smart wallets and apps continue to be introduced into ... in the mobile payment industry in focus today are:  NXT-ID, ... (NYSE: BABA ), Apple Inc. (NASDAQ: ... Facebook Inc. (NASDAQ: FB ) NXT-ID, ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6
... to spray venom into eyes of potential attackers. A ... reveals how these snakes maximize their chances of ... a bit of a misnomer. Cobras don,t actually "spit" ... of the Anatomical Laboratory in the Department of Physical ...
... researchers have identified a cellular mechanism that could someday ... Stephen Helfand and Nicola Neretti and others adds another ... biology, molecular biology, cell biology and biochemistry, first discovered ... the Indy ("I,m Not Dead Yet") gene that can ...
... NY, January 22, 2009--Biotechnology companies are building on ... the past decade and are expected to drive ... reports Genetic Engineering and Biotechnology News ... offers a number of advantages, including reducing reagent ...
Cached Biology News:Here's venom in your eye: Spitting cobras hit their mark 2Scientists unlock possible aging secret in genetically altered fruit fly 2GEN reports on growing reliance on microfluidics technology 2
(Date:4/16/2015)... Ames, IA (PRWEB) April 16, 2015 ... (CAST) announces that the prestigious 2015 Borlaug CAST ... honored faculty member at Tuskegee University in Alabama. ... by written material; public presentations; and/or the use ... excels in all three areas. As a specialist ...
(Date:4/16/2015)... 16, 2015 /CNW/ - Bioenterprise Corporation is pleased to announce ... Charlottetown , PEI.  Bioenterprise has established ... ADAPT Council for the commercialization of agricultural technologies and ... with PEI ADAPT.  They have been at the heart ... decade," explains Dave Smardon , President & CEO ...
(Date:4/16/2015)... Calif. , April 16, 2015  Scientists from ... "New Drugs on the Horizon," at the American Association ... Philadelphia, PA on Sunday, April 19, 2015 ... Ph.D., Cleave,s Director of Biology, will present new in ... a first-in-class, oral inhibitor of p97, a critical enzyme ...
(Date:4/16/2015)... Columbia and MENLO PARK, Calif. ... Inc. (OTCQX: DMPI) (DelMar and the Company), a ... therapies in new orphan drug indications, today announced that ... added as a clinical trial site for the ongoing, ... refractory glioblastoma multiforme (GBM), the most common and deadly ...
Breaking Biology Technology:The 2015 Borlaug CAST Communication Award Goes to Channapatna Prakash 2Bioenterprise Corporation Expands into the Maritimes 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5
... HEIGHTS, N.J., Nov. 26 Genta,Incorporated (Nasdaq: ... and,Chief Executive Officer, Dr. Raymond P. Warrell, Jr., ... activities at the Lazard Capital,Markets 4th Annual Healthcare ... at 8:00 am EST at the New York ...
... Inverness Medical,Innovations, Inc. (AMEX: IMA ) ... agreement to acquire ParadigmHealth, Inc. ParadigmHealth,headquartered in New ... care,and disease management services for acutely ill and ... patients., Commenting on the agreement, Ron Zwanziger, ...
... Unique Buying Opportunity Presented, CHARLES TOWN, ... (Pink Sheets: RBRM), a provider of treatment ... announced,it has successfully concluded analysis of the ... it to the Board of Directors., ...
Cached Biology Technology:Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference 2Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference 3Inverness Medical Innovations Agrees to Acquire ParadigmHealth 2Inverness Medical Innovations Agrees to Acquire ParadigmHealth 3ReBuilder Medical Technologies, Inc.'s Recent Stock Price Volatility Explained 2
Phospho-SEK1/MKK4 (Thr261) Antibody...
Rabbit polyclonal to Leucyl tRNA synthetase ( Abpromise for all tested applications). Antigen: L930-H1176 denatured human recombinant LRS. Entrez Gene ID: 3926 Swiss Protein ID: Q9P2J5...
Phospho-FADD (Ser194) Antibody (Human Specific)...
Rabbit polyclonal to MA2 ( Abpromise for all tested applications). entrezGeneID: 10687 SwissProtID: Q9UL42...
Biology Products: